When combined with AD, in which tau aggregation follows Aβ deposition, tauopathies afflict a significant proportion of the human population, and thus novel approaches to directly or indirectly block tau pathogenesis or its downstream effects are urgently needed. Here, MAPT is linked to Alzheimer disease.